Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act (“BPCIA”), asserting ...
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year. Regeneron's stock could soar by 50% in the next year from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback